Bind Therapeutics cancer, drug delivery news

Bind will reduce headcount by about 37 (38%) to 61 and restructure to reduce operating expenses. In December, the company said it will shift its focus from using its Accurins platform technology for improvement of existing chemotherapies’ therapeutic indexes to developing new drug candidates that incorporate combinations of tumor-directed ligands and payloads, including oligonucleotides and molecularly targeted therapies. The restructuring follows data from the Phase II iNSITE 1 and iNSITE 2 trials of BIND-014 in advanced non-small cell lung cancer (NSCLC) of squamous histology and cervical and head and neck cancers, respectively. Based on the data, the company said it intends to seek a partner for BIND-014 in NSCLC and halted further enrollment in the advanced cervical and head and neck cancers cohorts of iNSITE 2. In January, Bind discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of iNSITE 2. BIND-014 is a polymeric nanoparticle containing docetaxel that concentrates in the neovasculature surrounding tumors and targets prostate-specific membrane antigen ( PSMA; FOLH1; GCPII) (see BioCentury, Feb. 8).

Bind also said it is working with an investment bank to explore alternatives, including raising additional capital, a collaboration with one or more parties, licensing and sale or divestiture of some of the company’s technologies. The company said “there is no finite timetable for completion of the financial and strategic review process.” The company is also evaluating its options for its wholly owned subsidiary in Moscow. ...